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ABSTRACT 
Radiculopathy, a painful neuroinflammation that can accompany intervertebral disc herniation, is 
associated with locally increased levels of the pro-inflammatory cytokine tumor necrosis factor alpha 
(TNF Systemic administration of TNF antagonists for radiculopathy in the clinic has shown mixed 
results, and there is growing interest in the local delivery of anti-inflammatory drugs to treat this 
pathology as well as similar inflammatory events of peripheral nerve injury.  Curcumin, a known 
antagonist of TNF in multiple cell types and tissues, was chemically modified and conjugated to a 
thermally responsive elastin-like polypeptide (ELP) to create an injectable depot for sustained, local 
delivery of curcumin to treat neuroinflammation.  ELPs are biopolymers capable of thermally-triggered 
in situ depot formation that have been successfully employed as drug carriers and biomaterials in 
several applications.  ELP-curcumin conjugates were shown to display high drug loading, rapidly 
release curcumin in vitro via degradable carbamate bonds, and retain in vitro bioactivity against TNF-
induced cytotoxicity and monocyte activation with IC50 only two-fold higher than curcumin.  When 
injected proximal to the sciatic nerve in mice via intramuscular (i.m.) injection, ELP-curcumin 
conjugates underwent a thermally triggered soluble-insoluble phase transition, leading to in situ 
formation of a depot that released curcumin over 4 days post-injection and decreased plasma AUC 7-
fold.   
KEYWORDS 
Curcumin, conjugate, elastin-like polypeptide, sustained release, drug depot, neuroinflammation 
 
1. INTRODUCTION 
Intervertebral disc (IVD) herniation, or “ruptured disc,” is a common cause of low back pain that 
can cause significant back pain, radiating leg pain (a.k.a. sciatica or radiculopathy), neurological 
impairments, prolonged patient disability, and lost wages [1-3].  Painful symptoms from IVD herniation 
are believed to result from compression of the nerve root by extruded or prolapsed tissue, an 
inflammatory response to soluble factors within the IVD, or a combination of these two 
pathophysiologies [4-7].  At the biological level, radiculopathy and peripheral nerve injury are both 
characterized by neuroinflammation, immune system activation, and neuronal dysfunction [4, 8, 9].  
Following injury, resident macrophages called microglia in the spinal cord and dorsal root ganglion 
(DRG) are activated and release inflammatory cytokines, chemokines, and neurotransmitters that 
contribute to pain sensitization [10-12].  These biochemical signals attract peripheral immune cells, 
which infiltrate the injured nerve site, DRG, or ruptured disc and contribute to chronic inflammation and 
pain over time [9, 13, 14].  
Tumor necrosis factor alpha (TNFis a pro-inflammatory cytokine implicated as a key mediator 
of immune activation and neuroinflammation in radiculopathy and peripheral nerve injury.  TNF is 
secreted by multiple cell types in response to these injuries, both at the injury site and upstream in the 
DRG [15, 16], and these responses are, in part, regulated by nuclear factor kappa B (NF-B) activation 
[17].  TNF is expressed at higher levels in degenerated and herniated IVDs [18-23], and application of 
exogenous TNF to lumbar DRG in the rat [24, 25], much like animal models of compression-induced 
nerve root injury, can produce changes in nerve conduction velocity, microglial activation, and 
inflammatory mediator levels [24, 26].   
The central role of TNF in animal models of neuroinflammation has led to clinical interest in the 
delivery of TNF-blocking antibodies and TNF antagonists to treat IVD herniation-associated pain. 
However, the high costs and poor clinical results associated with systemic delivery of antibodies or 
soluble receptors to antagonize TNF have motivated interest in local drug delivery approaches [27-
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30], as well as alternative small-molecule compounds such as minocycline [31], neurotransmitter 
receptor antagonists [32, 33],  and resveratrol [34]. 
One such compound that has generated significant interest is curcumin, a natural product 
derived from the rhizome (turmeric) of the herb Curcuma longa with known anti-carcinogenic, anti-
bacterial, and anti-inflammatory activities [35].  At micromolar concentrations, curcumin suppresses 
TNF-induced or IL-1-induced activation of NF-B and downregulates cell adhesion molecules and pro-
inflammatory cytokines in multiple cell lines [36-43].  Recently, curcumin has been shown to be a potent 
modulator of the microglial transcriptome with an ability to alter the activation, migration, and pro-
inflammatory phenotype of microglia [44], cells which have been shown to be key initiators of 
neuroinflammatory pathology in models of radiculopathy and nerve injury [9, 10].  In addition to 
promoting a neuroprotective phenotype in microglia, curcumin demonstrates neuroprotective activity 
against IL-1 in rat DRGs at micromolar levels [45] and ameliorates neuropathic pain sensitivities in a 
mouse model of peripheral nerve injury [46]. Clinically, curcumin suffers from exceptionally low 
bioavailability due to low solubility and poor absorption into systemic circulation [47].  Many 
investigators have sought to make curcumin more soluble in aqueous solutions by developing structural 
derivatives [48-52], or incorporating insoluble curcumin particles into soluble nanoparticles [53]. To 
prolong systemic circulation of curcumin, investigators have entrapped curcumin in micro- or nano-
sized polymeric particles including poly(N-isopropylacrylamide) (poly(NIPAAM)) (i.e. nanocurcumin” 
[54, 55]), liposomes [56], micellar di-block copolymers [57-59], PLGA microspheres [60, 61], 
phosphatidylcholine-based phytosomes (Meriva®, Indena S.p.A., Milan, Italy) [62], and self-assembling 
peptide hydrogels [63].  Curcumin has also been chemically conjugated to drug carriers like 
poly(ethylene glycol) (PEG) [64], poly(amidoamine) (PAMAM) dendrimers [65], and incorporated into 
the polymer backbone of a hydrogel system via degradable carbonate bonds [66].   
In this study, curcumin was chemically modified to include a degradable carbamate linkage and 
a reactive primary amine, so that it could be coupled to a thermally responsive drug carrier, an elastin-
like polypeptide (ELP), for local, sustained release of bioactive curcumin to treat neuroinflammation.  
ELPs are thermally responsive biopolymers composed of a Val-Pro-Gly-Xaa-Gly pentapeptide repeat 
unit that is found to recur in tropoelastin, where Xaa can be any amino acid [67, 68].  ELPs undergo an 
inverse phase transition at a specified transition temperature (Tt), above which the ELP transitions from 
a soluble chain to an insoluble, viscous coacervate [69].  The Tt of a given ELP is primarily a function of 
amino acid composition, solution concentration, and molecular weight, but also depends on the solution 
pH, ionic strength, polarity of the solvent, and the presence of any fused proteins or conjugated 
molecules. ELPs have been employed as drug carriers and biomaterials in a variety of applications 
owing to its facile recombinant synthesis, biocompatibility, biodegradability, and non-immunogenic 
nature [70, 71].  In prior work, ELPs engineered to form depots at body temperature (Tt < 37 °C) were 
observed to reside in the perineural space of rats 7 times longer and reduce systemic exposure 14-fold 
compared to non-depot forming ELP [72].  ELPs have also been useful in forming intratumoral depots 
for local delivery of radionuclides [73, 74], as well as subcutaneous depots for systemic delivery of 
glucagon-like peptide-1 for treatment of diabetes [75].  For these reasons, we designed a 
biodegradable ELP-curcumin conjugate that would rapidly form a depot upon physiological 
administration and slowly release bioactive curcumin within the perineural space to treat 
neuroinflammation. This paper reports on the synthesis, physicochemical characterization, in vitro 
bioactivity, and in vivo pharmacokinetics and clearance rates of the conjugate. 
 
2. MATERIALS AND METHODS 
 
2.1 Materials and Reagents  
All reagents were purchased from Sigma Aldrich (St. Louis, MO), unless otherwise noted.  1-
Ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC), sulfo-N-hydroxysulfosuccinimide acetate (sulfo-
NHS-acetate), and SnakeSkin® Pleated Dialysis Tubing (MWCO 7000 Da) were purchased from 
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Pierce Biotechnology (Rockford, IL). Curcumin (95% purity) was purchased from Alfa Aesar (Ward Hill, 
MA), and fetal bovine serum (FBS) and phosphate-buffered saline (1X PBS) were purchased from 
Invitrogen (Gibco®, Carlsbad, CA).  
 
2.2 Chemical synthesis of Monofunctional Curcumin Carbamate (MCC) 
See supplementary section S.1. 
 
2.3 UV-VIS characterization of curcumin and MCC 
 The absorbance of curcumin and MCC standards was measured via UV-Vis spectrophotometry 
from 200 to 800 nm (CARY Bio 300 UV-VIS, Agilent Technologies, Santa Clara, CA).   The molar 
extinction coefficient of MCC at max = 416 nm (ɛ 416) was calculated for MCC samples diluted from 
100% acetonitrile (CH3CN) stocks into a cold UV-Vis buffer (50% H3CN: 50% DI H2O, pH = 7.4).  ELP 
was acetylated (AcELP) in a process described below, and AcELP was added to each MCC standard in 
a fixed molar ratio of 1 mole AcELP to 5 moles MCC to mimic ELP-MCC conjugates, as the presence of 
proteins such as albumin [76] have been shown to affect curcumin absorbance.  Absorbance of MCC 
with AcELP at 416 nm (OD416) was obtained and plotted against the known concentration of MCC, and 
ɛ 416 was determined from the linear regression of OD416 and concentration. 
 
2.4 Conjugate synthesis and purification 
Glutamate-rich ELPs with the amino acid sequence MSKGPG[VPGXG]L=60,80,160WPC with X = 
V/I/E [1:3:1] (MW = 26.3, 34.9, and 68.8 kDa), where L is the number of total pentapeptide repeats, 
were synthesized, expressed, and purified as previously described [77, 78].  Hydrophilic glutamate 
residues were periodically and precisely placed along the polymer backbone to provide carboxylates 
convenient for drug attachment; and we hypothesized that unreacted carboxylates remaining after 
conjugation would compensate for the increase in hydrophobicity following conjugation of curcumin 
(distribution coefficient at pH = 7.4, logDpH=7.4 = 2.9). 
 
2.4.1 Acetylation of ELP terminal amines 
To prevent intra- and inter-ELP chain crosslinking, the two terminal amine groups present on 
purified ELP (the amino terminus and the ɛ -amine of lysine) were blocked by reacting ELP in 1X PBS 
(pH = 8.3) at a concentration of 1 mM with sulfo-NHS-acetate (Pierce) dissolved in dimethylformamide 
(DMF) at a molar ratio of 25 to 1 acetates to amines for 1 h at room temperature.  The reaction solution 
was dialyzed against de-ionized H2O (DI H2O, pH = 7.1-7.4) for 48 h with at least 2 buffer changes, and 
the dialysate was frozen and lyophilized.  
 Blocking efficiency was confirmed with a 2,4,6-trinitrobenzene sulfonic acid (TNBS) assay [79].  
Dry AcELP and unmodified ELP were weighed and dissolved in a known volume of 0.1 M sodium 
bicarbonate (NaHCO3, pH = 8.3).  AcELP was diluted to 50 M and a standard curve of unmodified ELP 
ranging from 10-100 M was prepared.  TNBS acid stock was diluted to 0.01% acid in the same buffer 
and 50 l was added to 50 l of sample or standard in a 96-well plate.  The plate was incubated at 60 
°C (15 min.), allowed to cool at room temperature (5 min.), and absorbance was recorded at 340 nm 
(background correction at 595 nm) (Enspire Multimode Plate Reader, Perkin Elmer, Waltham, MA).  
Successful blocking was defined as a reduction in 340 nm absorbance by ≥ 90% of unmodified ELP. 
This process resulted in a net increase in molecular weight of 43 Da per acetyl group, or 86 Da per 
ELP. 
 
2.4.2 Conjugate synthesis 
ELP-MCC (AcELPL=60,80,160) conjugates were synthesized via carbodiimide coupling chemistry 
and termed MCC60, MCC80, or MCC160.  Briefly, dried AcELP, MCC, hydroxybenzotriazole (HOBt), 
and EDC were individually weighed and dissolved in DMF to insure a ratio of 6 moles MCC for 1 mole 
AcELP.  To the mixture of AcELP and MCC, HOBt and EDC in DMF were added in a 1.5 to 1 molar 
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ratio to MCC to react carboxylates of AcELP with the amines of MCC.  Reaction solutions were rotated 
at 4 °C in the dark for 18-24 h.  Reaction solutions were purified by dialyzing against pre-chilled DI H2O 
(pH = 7.1-7.4) for 24 h with 3 buffer changes.  The dialyzed conjugate was centrifuged (13.5 kRPM, 10 
min., 4 °C) to remove insoluble components, frozen, and lyophilized.  Purity was determined by high-
pressure liquid chromatography (HPLC), described below. 
2.5 Drug-to-carrier ratio characterization 
 A molar drug:carrier ratio for the ELP-MCC conjugate was determined as described here.  A 
mass of ELP-MCC (m) was dissolved in a known volume of UV-VIS buffer, and absorbance at 416 nm 
(OD416) and MCC MW were used to obtain the moles of MCC (nMCC) and mass of MCC (mMCC). A value 
for moles of AcELP in this solution (nAcELP) was determined from the dry weight attributed to AcELP (m-
mMCC) and the AcELP MW.  The molar drug:carrier ratio was thus reported as nMCC/nAcELP. 
 
2.6 Thermal characterization of conjugates 
 The thermal transition properties of ELP, AcELP, and ELP-MCC conjugates were measured by 
monitoring the optical density, or turbidity, of the solution at 650 nm on a thermally controlled UV-Vis 
spectrophotometer (CARY Bio 300 UV-VIS) as described previously [80]. OD650 was selected because 
curcumin does not absorb light at that wavelength.  Samples were diluted in 1X PBS (pH = 7.4) to 25 
M ELP and OD650 was monitored from 20 to 80 °C with a temperature ramping rate of 1 °C/min.  The 
transition temperature (Tt) was defined as the point at which the derivative of OD650 with respect to 
temperature was at its maximum value.  
 The mean particle diameters of ELP-MCC conjugates (25 M in 1X PBS, pH = 7.4)) were 
measured using dynamic light scattering (DLS, Zetasizer Nano ZS, Malvern Instruments, Malvern, 
Worcestershire, UK). Any particle subpopulation representing less than 2% of the total mass was 
excluded from analysis, and data were reported as the mean particle diameters with standard error 
representing the calculated polydispersity at each temperature.  
 
2.7 In vitro drug release and quantitation (HPLC) 
 In vitro drug release and conjugate purity was measured by reverse-phase HPLC (RP-HPLC) 
(LC10, Shimadzu, Kyoto, Japan) using a Phenomenex Aeris™ WIDEPORE XB-C18 column (4.6 mm X 
250 mm) and HPLC mobile phase (50% CH3CN: 50%DI H2O: 0.87% acetic acid, CH3COOH).  Samples 
were injected (100 l) with a flow rate of 0.6 ml/min and monitored at OD420.  Area-under-the-curve 
(AUC) and percent of total AUC (%AUC) for each peak of the chromatogram were analyzed with 
Shimadzu EZStart Software. 
 To quantify the kinetics of MCC release from the ELP-MCC conjugate, samples (MCC80, 50 
M) were diluted in a release buffer (10% (w/v) Tween-80, 0.1% (w/v) N-acetylcysteine (N-Ac), and 
0.01% (w/v) butylated hydroxytoluene (BHT) in 1X PBS at pH = 7.4) previously reported to promote 
stability of  curcumin [61].  To this release buffer, 10% FBS was added to test if serum proteins 
influenced MCC hydrolysis and/or ELP degradation.  Conjugates were divided into 50 l aliquots (25 
M MCC80 or 150 M MCC) and incubated in the dark at 37 °C.  At multiple time points (0, 1, 2, 4, 24, 
48, 72, 96 h; n = 4 replicates), one aliquot was removed from heat, cooled on ice to resolubilize ELP (5 
min), diluted 1:3 in mobile phase, and stored at -20 °C before analysis.  After thawing and before 
analysis, samples were centrifuged (13.5 kRPM, 10 min, 4 °C) to remove any precipitates.  
 Aliquots were analyzed via HPLC and converted to concentrations using standard curves for 
MCC80 and curcumin to determine the curcumin concentration in the supernatant. The resulting 
concentrations were normalized to the loaded concentration and converted to percent drug released, C, 
which was plotted as a function of time and fit to a first-order release equation, C = Cf [1-e
-t/], to 
determine the release half-life t1/2 = ln(2).    Release data was numerically fit to the above equation 
(Matlab, function cftool) to calculate the fit parameters Cf, the final percent drug released, and t1/2.  
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2.8 In vitro cytoprotection against TNF 
  A murine L929 fibrosarcoma (ATCC) cytoprotection assay [81] was used to screen in vitro drug 
bioactivity of curcumin and MCC80 conjugates against TNF.  The assay was performed as previously 
described [82], with modifications to accommodate the low aqueous solubility of curcumin.  Curcumin 
stocks were prepared in DMSO and MCC80 stocks were prepared in sterile 1X PBS.  Cells were  pre-
incubated with 1 g/ml of actinomycin D (1 h) after which individual wells were supplemented with 250  
pg/ml recombinant human TNF (rhTNF) in 2% DMSO (Abcam, positive control), an equivalent media 
volume with 2% DMSO (negative control), or volumes containing TNF with MCC80 or curcumin [0.5 to 
25 M]. 
After 24h incubation, cell numbers were assessed using the ATP-dependent bioluminescent 
CellTiterGlo® Assay (Promega).  A standard curve of luminescence against cell number was obtained 
using L929 cells (0-50,000 cells/ well) on a plate reader.  From luminescence per experimental well, a 
subtracted cell number per well was determined as the difference between cell number (N) and 
maximum cell numbers without TNF or N = N - Nnegative.   A normalized cell fraction, X, was 
calculated for each drug at each dose as XN/Nmax where Nmax represents the difference in cell 
numbers due to TNF supplementation alone (positive control).  X was plotted against curcumin or 
MCC80 concentration and numerically fit to a logistic curve (Matlab, function cftool) to calculate a half-
maximal inhibitory concentration (IC50) for curcumin and MCC80, separately,  
       (1) 
The Hill slope, k, and b are fit parameters and the IC50 (X = 0.5) is equal to b
(1/k).  
2.9 In vitro inhibition of human monocyte NF-kB phosphorylation 
Human monocytes (U937, ATCC) were cultured in suspension in U937 culture medium (RPMI-
1640 medium with 10% FBS and 100 g/ml penicillin and streptomycin) and not allowed to grow to 
confluence prior to cell seeding.  Cells were resuspended in U937 assay medium (Hank’s Balanced 
Salt Solution (HBSS, Gibco) with 1% FBS) and 40 l of cells were seeded in 96-well plates (400,000 
cells/well, n=3 replicates).  U937 cells then received 20 l of U937 assay medium with or without 
curcumin or MCC80 in 2% DMSO at a high (5 M) or low (0.5 M) concentration.  Cells were pre-
incubated for 2 h at 37 °C.  At that time, 20 l of U937 assay medium with or without rhTNF (final 
concentration of 50 ng/ml) was added to each well and incubated for 10 min. at 37 °C.  Lysis buffer (20 
l, 5X concentrated) was added to each well, plates were agitated for 10 min. at room temperature, cell 
lysate (30 l) was transferred to a fresh 96-well white-bottom plate, and the levels of phosphorylated 
NF-B p65 were quantified using an AlphaScreen® SureFire HVTM AlphaLISA (Perkin-Elmer).  
Data were normalized to the negative control (no TNF, no drug) and differences in 
phosphorylated NF-B p65 across treatment groups were detected using one-way ANOVA with post-
hoc Tukey’s HSD tests (JMP10, SAS Institute, Cary, NC, USA).  
 
2.10 In vivo pharmacokinetics and drug clearance rates following perineural delivery 
All animal studies were conducted following protocols approved by the Duke Institutional Animal 
Care & Use Committee.  Animals were anesthetized with isoflurane, and curcumin or MCC80 (40 l, 
6mM) was delivered by intramuscular (i.m.) injection using a 50 l Hamilton syringe with a sterile 27-
gauge needle into the left thigh, adjacent to the sciatic nerve of female C57BL/6 mice (12-15 weeks, n 
= 2 or 3 per group, Charles Rivers Laboratories, Durham, NC).  Curcumin was suspended in DMSO 
and MCC80 was suspended in sterile 1X PBS.   
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
  Sinclair et al., A Thermally Responsive Curcumin Depot for Neuroinflammation 
 
 
  6  
 
For pharmacokinetic studies, animals were serially bled via the maxillary vein to collect 50-100 
l of whole blood over time (0.5 to 96 h).  Blood was collected in EDTA-containing BD Vacutainer® 
microvials (BD, Franklin Lakes, NJ), inverted, immediately centrifuged (4 °C, 3500 RPM, 15 min), and 
plasma fractions were transferred to 2 mL cryovials (Corning Inc., Corning, NY) and stored at -80 °C. 
Protocols for the detection and quantitation of curcumin in plasma can be found in section S.2. The 
concentration of curcumin in plasma was plotted over time for each animal, and the AUC for each 
animal (nM*h) was calculated using the trapezoid method for only those time points where curcumin 
levels were above detection limit.  To account for plasma autofluorescence that may contribute to total 
AUC, a corrective factor, AUCnaive = LLD*(final timepoint-initial timepoint), was calculated and 
subtracted from each individual AUC.  These corrected AUC values were used to calculate the mean 
AUCCurc and mean AUCMCC80.   
For clearance studies, the injection site was defined to include the sciatic nerve segment at the 
mid-thigh (~5-10 mm), muscles dorsal and ventral to the nerve segment, and the dorsal skin and 
subcutaneous layers surrounding the point of needle entry. Animals were sacrificed at 2, 48, and 96 h 
by exsanguination to collect blood, after which all tissues from the injection site were harvested. To 
quantify a maximum recoverable percent of injected dose from tissues at time zero (%ID max), two 
naïve animals were injected (i.m.) with curcumin or MCC80 just after sacrifice and tissues were 
immediately harvested.  Protocols for the detection and quantitation of curcumin from tissue samples 
can be found in section S.3. Concentrations of curcumin in tissue samples were converted to mass 
(nmol) using the known volume of tissue buffer added, mass per grams of tissue (nmol/g), and %ID 
(nmol/nmol*100%) for comparison. 
Differences in plasma concentrations, plasma AUC, and drug masses in harvested tissue (nmol) 
between curcumin, MCC80, and naïve plasma groups were analyzed by one-way ANOVA (JMP10) 
with post-hoc Tukey’s HSD tests. 
 
RESULTS 
3.1 Synthesis of MCC  
MCC was successfully synthesized by a 3-step reaction shown in Figure 1.  Formation of a 
reactive carbonate intermediate, followed by reaction of the intermediate with N-boc-ethylenediamine, 
yielded a mono-protected curcumin carbamate.  Analysis of the reaction mixture by thin layer 
chromatography indicated complete consumption of curcumin, and electrospray ionization mass 
spectrometry (ESIMS) indicated one peak with the expected mass of the mono-protected curcumin 
carbamate (m/z = 554 ([M+H]+)). This product was deprotected using standard techniques to yield the 
desired final product, MCC (Figure S1, ESIMS m/z = 455 ([M+H]+)).  The structure of MCC was further 
confirmed with 1H-NMR (Figure S2).   
 
Figure 1. Reaction schematic for the synthesis of MCC from curcumin. 
 
3.2 Absorbance properties of curcumin and MCC 
The absorbance spectra of curcumin and MCC in UV-Vis buffer were measured in the presence 
of AcELP in a molar ratio of 5 to 1 MCC to AcELP (Figure 2).  In the presence of AcELP, the 
wavelength of maximum absorbance, max, for curcumin was found to be 425 nm, and max for MCC 
was found to be blue-shifted to 416 nm.  At the same concentration, the maximum absorbance of MCC 
in UV-Vis buffer was 50% lower than for curcumin, indicating the change in structure of MCC hinders its  
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ability to absorb light. The molar extinction 
coefficient of MCC at 416 nm, 416, in the 
presence of AcELP was calculated to be 
31806 M-1cm-1.    
 
3.3 Acetylation of ELP N-terminal 
amines 
 Glutamate-rich ELPs were reacted 
with sulfo-NHS-acetate to block the two N-
terminal amines present on ELP, which 
were found to contribute to excessive 
intra- and inter-chain crosslinking when 
left unblocked.  When sulfo-NHS-acetate 
was added in large excess (25 moles 
acetate to 1 mole amine), the reaction 
resulted in the irreversible addition of an 
acetyl group (43 Da) to each amine of 
ELP, which was confirmed for each batch 
using the TNBS assay. 
 As the thermal transition 
temperature (Tt) of ELPs is dependent 
upon the hydrophobicity of the polymer chain, the addition of small, hydrophilic acetyl groups led to a 2-
4 °C increase in the Tt  of each AcELP at the concentrations tested (Table 1).  Differences in ELP 
transition kinetics and reversibility were not detected for AcELP compared to unmodified ELP for all 
sizes.  
 
3.4 Characterization of ELP-MCC conjugates 
3.4.1 Drug-to-carrier ratios 
 The mean drug-to-carrier ratio for MCC60 and MCC80 was 7.2 ± 0.2 and 5.9 ± 0.2, indicating 
that approximately 5 or 10 glutamates remained unconjugated, respectively (Table 1, mean ± SEM, 
n=3 batches).  Preliminary reactions of MCC with ELPL=160 had low yields and ratios below unity, so 
further studies of MCC160 were not pursued.  HPLC was used to verify that there was no more than 
5% unreacted MCC or recently released curcumin in each batch for each ELP.  
Table 1. Characterization of ELP, AcELP, and ELP-MCC Conjugates 
Length, 
L 
MW 
(kDa) 
Tt (ELP) 
(°C) 
Blocking 
(%) 
Tt (AcELP) 
(°C) 
MCC:ELP 
Ratio 
Tt (ELP-MCC) 
(°C) 
60 26.3 >80 72 >80 7.2 54 
80 34.8 72 90 76 5.9 40 
160 68.7 63 84 65 0.8 39 
ELP contain 13, 17, or 33 carboxylic acids, respectively, when including the C-terminus.  % blocking for 
AcELPL=60,160 were below 90%, but high and low concentrations of each AcELP were not different from the 
lowest standard tested.  Purity of MCC60 and MCC80 were both ~95%, as measured by HPLC.  T t are reported 
for 25 M ELP or AcELP for all cases. Drug-to-carrier ratios for MCC60 and MCC80 represent the mean ratio of 
n = 3 separate batches. 
 
 
 
 
Figure 2. Absorbance spectrum of curcumin and MCC in UV-
Vis buffer at the same concentration in the presence of AcELP.  
(Inset) Linear regression fit of MCC standards to Beers-
Lambert law (A = cl) to calculate 416 for MCC (n = 3 tests, 4 
scans per test, R
2 
= 0.9712). 
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 3.4.2 Thermal transition properties of 
ELP-MCC conjugates 
   
Curcumin is a highly 
hydrophobic molecule, and hence was 
expected to decrease the Tt of ELP-
MCC conjugates.  ELP-MCC 
conjugates are thermally responsive, 
with Tt of 40 °C or 54 °C for MCC80 
and MCC60, respectively, at 25 M.  At 
therapeutically relevant doses (>100 
M ELP), MCC80 conjugates exhibit a 
Tt ≤ 37°C, which is ideal for in situ-
gelling therapeutics (Figure 3).   The Tt 
of MCC80 conjugates dropped by 35 
°C, or ~6°C/molecule MCC, which is 
consistent with the reported effects of 
other hydrophobic molecules, such as 
doxorubicin, on the Tt of ELP-Dox 
conjugates [80, 83].  At a concentration 
of 1 mM, MCC80 conjugate Tt 
appeared to deviate from the logarithmic dependence of Tt on concentration [84]. The Tt of MCC60 
conjugates also dropped significantly, though not enough to be useful for an injectable, local delivery 
application, even after resuspending at millimolar concentrations.  Therefore, MCC60 conjugates were 
not characterized further or included in pharmacokinetic and clearance studies. 
 The mean particle diameters for conjugates were determined by DLS.  ELP and AcELP 
(L=60,80,160) monomers displayed diameters < 20 nm below the Tt and aggregated into submicron-
sized particles above the Tt (not shown).  Below Tt, MCC80 conjugates were observed as two 
populations with mean particle diameters of 16.8 nm ± 3.7 nm or 251 nm ± 120 nm, which represented 
43% or 57% of the total mass, respectively.  Above Tt, the entirety of the sample mass was observed 
as submicron-sized particles with mean particle diameter of 631 nm ± 50.0 nm (Figure S3). 
 
3.4.3 In vitro release of curcumin from MCC80 
conjugates  
In vitro release studies of MCC80 conjugates 
were conducted in a solubilizing release buffer that 
was modified with 10% FBS, which introduced 
proteases and esterases likely to impact in vivo 
release kinetics.  MCC80 conjugates released 
whole-length curcumin with the same elution time 
and profile as native curcumin using the HPLC 
methods described here. Curcumin was rapidly 
released from MCC80 depots in vitro (Figure 4), with 
55% of loaded curcumin released after 96 hours at 
37°C. The half-life of curcumin release, t1/2, from 
MCC80 depots was calculated to be 7.1 hours.  
 
3.4.4 Dose-dependent cytoprotection of curcumin 
and conjugates against TNF 
 
Figure 3. Rapid thermally-triggered phase transition of MCC80 
conjugates below physiologic temperatures.  A) MCC80 was 
resuspended at 1 mM conjugate (6 mM MCC) in 1X PBS (pH = 
7.4) and heated at a constant rate of 1 °C/min while monitoring the 
solution turbidity (OD650). B)  MCC80 displayed significantly lower 
Tt than AcELPL=80. Concentrations of MCC80 at or above 100 M 
exhibited Tt ≤ 37°C. 
 
Figure 4. In vitro release of curcumin from MCC80 
conjugates in a release buffer with 10% FBS.  
Numerical fit: R
2
 = 0.88; Leq = 55.26 [49.17, 61.35]; 
t1/2 = 7.154 [3.36, 10.9]. Brackets indicate 95% CI. 
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 MCC80 conjugates retained bioactivity 
against TNF and displayed a dose-dependent 
ability to protect L929 cells from TNF-induced 
death (Figure 5).  IC50 values for curcumin and 
MCC80 were calculated to be 13.5 M and 24.1 
M, respectively.  The minor decrease in 
bioactivity of conjugates may be related to the 
decreased availability of drug trapped in depots 
or the delayed diffusion of drug to the target 
cells from depots.  It should be noted that no 
organic solvent (DMSO) was required to 
solubilize the highest doses of MCC80, which 
indicated that ELP conjugation results in 
enhanced curcumin solubility.  ELPL=80 and 
AcELPL=80 had no effect on L929 cell 
proliferation over 24 h, but doses of curcumin in 
DMSO above 30 M had some cytotoxic effects, 
owing to the insolubility of the compound at 
these higher concentrations (not shown). 
 
3.4.5 Dose-dependent inhibition of monocyte 
NF-B phosphorylation 
 
The ability of curcumin and MCC80 to 
inhibit NF-B p65 phosphorylation was 
investigated using an human monocyte cell line (U937) previously used to study the inhibitory effects of 
curcumin against TNF[85].  Peak increases in TNF-induced NF-B phosphorylation was separately 
observed to occur 10 minutes after exposure to TNF(not shown).  As shown in Figure 6, U937 cells 
displayed 7.3-fold increases in phosphorylated NF-B after 10-minute incubation with  
 
Figure 5. Dose-dependent anti-TNF bioactivity of 
MCC80 and curcumin in the L929 cytoprotection assay.  
Data was fit by nonlinear least-squares regression to 
Equation 1 to calculate IC50 values.  The IC50 of MCC80 
was almost 2-fold higher than curcumin; however, the 
95% confidence intervals for each drug overlap 
substantially.  MCC80 numerical fit: b = 237.6; k = 1.72; 
IC50 = 24.1 M [19.1, 32.0]; R
2 
= 0.98.  Curcumin 
numerical fit: b = 45.95; k = 1.472; IC50 = 13.5 M [10.1, 
19.0]; R
2 
= 0.98.  Brackets indicate 95% CI. 
 
Figure 6. Attenuation of TNF-induced human monocyte NF-B p65 phosphorylation with curcumin and MCC80.  
High and low doses of curcumin and MCC80 had no statistically significant effect on basal NF-kB phosphorylation 
compared to controls, but were able to attenuate TNF-induced increases in NF-kB phosphorylation in a dose-
dependent manner (mean ± SEM, n = 3 replicates). * = different from TNF only, one-way ANOVA, p < 0.0001. 
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TNF (50 ng/ml, n = 3 assays, 1-3 replicates per assay).  This TNF-induced activation of monocyte NF-
B was equally attenuated with high micromolar doses of curcumin and MCC80 conjugates (Figure 6).   
3.4.6 In vivo pharmacokinetics and drug clearance rates for MCC80 conjugates  
   
 Curcumin and MCC80 were 
delivered proximal to the sciatic nerve in 
mice via i.m. injection and drug levels were 
tracked in plasma and tissue over time.  
The lower limit of detection (LLD) for the 
plasma fluorescence assay was found to 
be 22 nM for the plate reader assay, which 
corresponds to a final concentration of 176 
nM after accounting for sample dilution. 
Curcumin was detected in plasma out to 4 
h following injection (Figure 7), with 
maximum plasma levels Cmax = 590 nM ± 
40 nM and 260 nM ± 3.0 nM for free 
curcumin and MCC80, respectively (n=2 or 
3 animals, mean ± SEM).  Cmax levels 
occurred at a time, tmax, of 1-2 h for both 
curcumin and MCC80, which is similar to 
oral [86] and subcutaneous delivery [61] of 
curcumin in mice reported elsewhere. 
Plasma concentrations for curcumin, 
MCC80, and naïve plasma for all time-
points less than 24 h were statistically 
different from each other, and AUCMCC80 
was measured to be 7-fold lower than 
AUCCurc, indicating that less total curcumin 
entered the systemic circulation during the first day when it was administered in a depot. 
At 2 h, 48 h, and 96 h, animals were sacrificed to harvest injection site tissue and measure 
curcumin clearance rates over time.  Figure 8 shows the gross appearance of curcumin in DMSO and 
MCC80 depots proximal to the sciatic nerve 2 h after i.m. injection.  Both groups appeared to localize 
around the sciatic nerve following injection, and MCC80 depots were observed as an orange-yellow 
gel.  Curcumin from MCC80 conjugates cleared from the injection site in a sustained manner.  At each 
time point, MCC80 was detected in depot form by both visual inspection and HPLC analysis of 
solubilized tissues. Table 2 shows the maximum recoverable mass at time t = 0, as well as the 
measured masses of curcumin found within tissues at each time point for each group.  Based upon the 
methods reported here, a greater %ID from free curcumin in DMSO delivered by i.m. injection remained 
at the site of injection at 2 h compared to MCC80, though there was no statistical significance between 
groups.  At this time, free curcumin appeared completely insoluble and in macroscopic particles (Figure 
8), indicating that the DMSO vehicle had likely been exchanged for interstitial fluids, rendering curcumin 
insoluble.  This insolubility favored lower initial clearance rates of curcumin compared to MCC80.  
HPLC analysis of a subset of MCC80 solubilized tissue samples indicated that, for 16 out of 21 
samples, >95% of curcumin was still bound to ELP at the time of harvest (not shown).  Only samples at 
2 h after injection contained a mixed population of free and bound curcumin.  At 48 h and 96 h, 5-fold 
more curcumin was detected for MCC80 compared to free curcumin, and depots of MCC80 were still  
 
Figure 7. Plasma pharmacokinetics of curcumin following 
delivery proximal to the sciatic nerve via i.m. injection (n = 2 or 
3, mean ± SEM). Naïve plasma mean (146 nM) is plotted ± 
2SD [116 nM, 177 nM] in shaded region. Values for curcumin 
and MCC80 were statistically significant from naïve plasma 
from 0.5 to 4 h (one-way ANOVA, Jump, p < 0.0001). For 
curcumin: AUC = 870 ± 130 nM*h. For MCC80: AUC = 127 ± 
26 nM*h. * = different from naïve plasma and MCC80; # = 
different from curcumin and naïve plasma.    
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visible at 96 h, indicating that conjugation 
of curcumin to ELP does provide for 
sustained release of curcumin following 
local perineural delivery. 
 
3. DISCUSSION 
 TNF plays a central role in the 
local neuroinflammation and pain 
sensitization associated with 
radiculopathy and peripheral nerve 
injury[5, 9], which has led to significant 
clinical interest in the use of TNF 
antagonists for treating these conditions 
[27, 28].  Systemic administration of these 
drugs has shown minimal efficacy and 
has motivated efforts to develop local 
drug delivery strategies that can both 
increase drug residence time at the site of 
pain and inflammation and decrease 
systemic exposure of immunosuppressants [29, 30, 87].  Curcumin is a natural product with an 
excellent safety profile that has known activity against TNF via inhibition of NF-B activation [36].  
However, curcumin suffers from low aqueous solubility and bioavailability [47], which has led many 
investigators to develop drug delivery systems for entrapping or conjugating curcumin to a drug carrier 
to improve pharmacokinetics and preclinical efficacy [54, 57, 61].   
In this study, curcumin was chemically modified and bound to a thermally sensitive ELP 
biopolymer that experiences a sharp and rapid soluble-to-insoluble phase transition at a temperature 
below 37 °C [67, 68].  This unique characteristic allows the ELP-curcumin conjugate to be easily 
handled and injected at room temperature when ELP is fully soluble and then promotes a rapid 
transition into an immobile viscous coacervate upon warming to physiological temperature.  The ELP- 
curcumin conjugates 
described here were shown 
to maintain thermally-
triggered depot formation 
after curcumin conjugation, 
to readily release curcumin 
in vitro and in vivo, to retain 
bioactivity against 
TNFand to contribute to a 
sustained delivery of 
curcumin over 4 days 
following intramuscular 
injection proximal to the 
sciatic nerve in mice, while 
decreasing Cmax and plasma 
AUC of curcumin 7-fold.  
When delivered to less 
perfused and more isolated 
compartments, such as the 
perineural space or epidural 
 
Figure 8. Biopsies of curcumin and MCC80 proximal to sciatic 
nerve 2 h after i.m. injection.  Curcumin in DMSO appears as 
insoluble aggregates, while MCC80 appears as a soluble gel 
around the nerve. 
Table 2. Tissue clearance rates for curcumin and MCC80 
Group 
Time 
(h) 
Mass 
(nmol) 
Mass 
(nmol/g tissue) 
%ID 
(nmol/nmol) 
Curcumin 0* 158 765 59 
 2 98 ± 24 531 ± 81 36 ± 8.9 
 48& 0.67 ± 0.004 7.2 ± 1.3 0.25 ± 0.002 
 96 0.39 ± 0.12 2.8 ± 0.95 0.14 ± 0.04 
MCC80 0* 90 1080 33 
 2 33 ± 8.1 280 ± 73 12 ± 3.0 
 48 3.5 ± 1.2 37 ± 10 1.3 ± 0.46 
 96 2.2 ± 0.32 15 ± 2.1 0.80 ± 0.12 
*=0 h validations were conducted for n=1 animals per group and not included 
in statistical analyses. All other time points represent n = 3 animals per group 
(mean ± SEM), except where outliers were removed due to injection error (n = 
2
&
). There were no statistical differences between curcumin or MCC80 (one-
way ANOVA, p = 0.2). 
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space, release of curcumin from ELP-curcumin conjugates may be sustained for longer periods and 
allow for weekly delivery of TNF antagonists to treat neuroinflammation.   
To synthesize ELP-curcumin conjugates, curcumin was first chemically modified to include a 
reactive primary amine connected by a carbamate linkage, termed monofunctional curcumin carbamate 
(MCC).  With this chemical modification, we generated a more soluble curcumin variant and enabled 
facile conjugation of curcumin to a variety of carrier compounds with a built-in carbamate bond that is 
susceptible to hydrolysis and aminolysis [88].  The reported 3-step synthetic schematic employed a 
carbonate intermediate that can react readily with any primary amine, meaning many modified 
curcumins could be easily synthesized with distinct carbamate linkers and reactive end-groups.  The 
linker structure of MCC was chosen for its simplicity and as a proof-of-concept of this approach to 
conjugate design.   
The modifications to curcumin reported here had modest effects on the absorbance properties 
of MCC and somewhat increased the hydrophilicity of curcumin, owing to the hydrophilic carbamate 
and amine groups.  Curcumin has been previously modified by conjugation of single amino acids to 
form monovalent or divalent curcumin bioconjugates that have increased solubility and anti-microbial or 
anti-mutagenic bioactivity in vitro [51, 52].  Other investigators have created libraries of curcumin 
variants by modifying the hydrocarbon backbone and screening these libraries for compounds with 
increased anti-angiogenic or chemotherapeutic activity [48, 49].  These strategies have proven to be 
effective methods for increasing curcumin solubility and discovering novel small molecule drugs, and if 
coupled with sustained drug delivery systems, could prove useful for local delivery applications like 
neuroinflammation.   
We hypothesized that conjugation of curcumin, a very hydrophobic drug, to AcELP would 
dramatically drop the Tt of AcELP, as was observed for ELP-doxorubicin conjugates [83].  Based upon 
this hypothesis, highly hydrophilic glutamate-rich ELPs were chosen for this conjugation strategy, which 
were previously developed for pH-responsive drug delivery applications [78].  The added presence of 
acetyl groups on ELPs, necessary for MCC conjugation, led to minor increases in Tt, which was 
expected given the hydrophilicity of acetyl groups.  The carboxyl groups of glutamate residues on 
AcELP were reacted with the primary amines of MCC via carbodiimide chemistry to form ELP-MCC 
conjugates with a pendant chain structure.  As we hypothesized, conjugation of MCC to AcELPs led to 
an average drop of 6 °C/molecule of MCC. Interestingly, the Tt of MCC80 at 1 mM somewhat deviated 
from the logarithmic dependence of ELP Tt on concentration previously reported for many ELPs [78, 
84].  This observation may be due to the coupling of hydrophobic MCC molecules that likely alter the 
thermodynamics of ELP aggregation, especially at high concentrations. 
In a majority of studies published, micromolar concentrations of curcumin were required to elicit 
a biological response from a given cell type.  Therefore, curcumin must be delivered at high doses in 
order to be efficacious.  The ELP-MCC conjugates reported here were measured to have drug-to-
carrier ratios of 6- or 7-to-1 for low- and mid-MW ELP, respectively, and be soluble at millimolar 
concentrations without the addition of organic solvents.  These drug-to-carrier ratios suggest an ability 
to deliver a releasable form of curcumin at millimolar concentrations directly to the injury site and for 
sustained periods of time.   
The drug-to-carrier ratio of recovered, purified conjugates appears to be limited to these values, 
however, by the resulting solubility of heavily coupled ELP conjugates.  Conjugates formed by reacting 
at higher MCC-to-ELP ratios were insoluble and could not be purified using the methods described 
here, which may indicate a substantial drop in Tt or an increased domination of hydrophobic 
interactions for incremental increases in drug-to-carrier ratio.  This limitation could be overcome by 
redesigning the ELP sequence to make it initially more hydrophilic, or sequestering the reactive 
carboxyls to one region of the ELP chain (e.g. diblock design).  Interestingly, conjugation reactions with 
large-MW AcELP (L = 160) yielded very low ratios (< 1), which may be related to the lower starting Tt of 
AcELPL=160 compared to the low- and mid-MW AcELPs.  
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MCC80 conjugates readily released curcumin in vitro when suspended in a stabilizing release 
buffer.  Analysis of release study supernatants with HPLC confirmed that full-length curcumin was 
released.  Given the minor loss of curcumin with each transfer step during the release experiment and 
HPLC analysis, total curcumin release would never reach 100% of loaded drug using the methods 
described here. Curcumin released from MCC80 conjugates retained bioactivity against TNF-induced 
cytotoxicity in the L929 fibrosarcoma assay and TNF-induced NF-B phosphorylation in human U937 
monocytes.  These results corroborate previous studies of the inhibitory activity of curcumin against 
TNFand NF-B activation in multiple cells types including microglia [44], and suggest that locally 
delivered curcumin may limit the inflammatory activity of infiltrating macrophages to the site of nerve 
injury in models of neuroinflammation.  In order to test high doses of curcumin, all wells received 2% 
DMSO, which was shown to not adversely affect cell proliferation. Conjugation of MCC to AcELP 
increased the solubility of curcumin, such that no DMSO was required for in vitro bioactivity assays or in 
vivo injections of millimolar concentrations of curcumin.  MCC80 conjugates were calculated to have a 
slightly higher IC50 value in the same assay, but the 95% confidence intervals for both drugs overlapped 
at almost all concentrations. The minor decrease in bioactivity of conjugates may be related to the 
decreased availability of drug trapped in depots or the delayed diffusion of drug to the target cells from 
depots.   
Other local delivery strategies for curcumin have been developed and studied in vitro, including 
a curcumin-eluting stent [89], self-assembling peptide hydrogels [63], and incorporation into a hydrogel 
polymer backbone via degradable carbonate bonds [66].  When curcumin is entrapped rather than 
conjugated, higher drug loading can be achieved, which may assist with efficacy for applications such 
as tumor-killing [63].  Incorporation of curcumin into the backbone of PEG-based hydrogels via 
carbonate bonds led to near zero-order in vitro release kinetics over 80 days, and released curcumin 
demonstrated cytotoxicity against multiple cancerous cell types [66].  Curcumin could be loaded at high 
concentrations, while still allowing the hydrogel systems to swell and imbibe water, making these gels a 
good candidate for local delivery as a soft tissue filler following tumor resection. This study takes these 
efforts to develop local, sustained drug delivery strategies for curcumin one step further by reporting the 
in vivo pharmacokinetics and clearance rates of curcumin from a local depot. 
The clearance kinetics reported for MCC80 were limited by the method of extraction and 
detection, as recovery of curcumin and MCC80 at 0 h was only 59% or 33%, respectively.  This finding 
indicates that recovery and quantification of MCC80 in tissues was likely poor for all time points studied, 
and studies of the clearance rates of MCC80 compared to curcumin require further evaluation. These 
lower values may reflect, in part, challenges due to extracting curcumin from tissues using solubilization 
and centrifugation procedures, which were modified from previous pharmacodynamics studies of ELP-
doxorubicin [83].  Delivery of ELP-curcumin to a less perfused and more isolated compartment, such as 
the perineural or epidural space, may facilitate retention of the curcumin in depot form above that which 
was measured here via i.m. delivery.  Furthermore, the extensive previous success of ELP as a drug 
carrier for subcutaneous, intravenous, intra-tumoral, intra-articular, and perineural delivery are 
encouraging, and our own visual observations of ELP-curcumin depots at the injection site 4 days after 
delivery should be emphasized (Figure 8).  In the future, the efficacy of local, sustained delivery of ELP-
curcumin conjugates to the perineural space in an animal model of neuroinflammation will be 
investigated. 
 
CONCLUSION 
 Local delivery strategies for many hydrophobic drugs such as curcumin are becoming more 
popular to overcome poor bioavailability and achieve a high drug concentration at the site of action, 
while remaining cost-effective.  Likewise, local delivery strategies for treating radiculopathy and 
peripheral nerve injury are gaining support, given the limitations of systemic administration of TNF 
inhibitors.  We chose curcumin because it possesses a wide range of anti-inflammatory properties 
relevant to neuroinflammation but has typically limited in vivo efficacy owing to its poor bioavailability 
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and low solubility.  Motivated by these reasons, injectable, thermally-responsive ELP-curcumin 
conjugates were synthesized and characterized for the purpose of providing local and sustained 
release of curcumin to treat neuroinflammation pathologies such as IVD herniation-associated 
radiculopathy or peripheral nerve injury. Upon injection, the physiological temperature triggered the 
ELP-curcumin conjugate to form depots at the site of administration that displayed a sustained release 
of bioactive curcumin in vitro and in vivo.  ELP-curcumin conjugates retained in vitro bioactivity against 
TNF formed depots in vivo following i.m. injection proximal to the sciatic nerve in mice, and provided 
sustained, local delivery of curcumin while limiting the systemic exposure of curcumin.  However, our 
strategy to modify and deliver curcumin could be applied to any polyphenol, such as naturally-derived 
resveratrol, green tea polyphenols, and flavonoids.  Furthermore, the MCC linker structure and reactive 
end-group represent a versatile strategy to couple these drugs to a variety of carriers. In conclusion, 
ELPs are an excellent drug carrier for such applications, and further studies of in vivo efficacy of ELP-
curcumin conjugates in a model of peripheral nerve injury will be investigated. 
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